Tradestie Institutional Equity Comparison Engine

EVGN vs CLYM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CLYM Overall Edge

CLYM Captures Institutional Edge (2โ€“0 Pillars ยท 7โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, EVGN trades at N/M Forward P/E with -858.2% operating margin (-60.7% YoY revenue) versus CLYM at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EVGN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
EVGN N/M vs CLYM N/M Fwd P/E
Growth & Margin Winner CLYM
Op Margin -858.2% vs 0.0% ยท YoY -60.7% vs +0.0%
Momentum & Technical Winner CLYM
1Y -71.9% vs +414.7% ยท 52W Pos 9% vs 49%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
EVGN NASDAQ
Evogene Ltd.
Agricultural Chemicals
$0.34
-13.17% 1D
Market Cap $6.0M
1M Return -7.58%
1Y Return -71.89%
Forward P/E N/M
Unified AI Score
44.1 / 100 HOLD
Tech 42.0 Fund 44.0 Flow 50.0 Mom 60.0
CLYM NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.78
-1.61% 1D
Market Cap $583.9M
1M Return +0.51%
1Y Return +414.74%
Forward P/E N/M
Unified AI Score
51.0 / 100 HOLD
Tech 65.0 Fund 47.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EVGN -71.89% CLYM +414.74% Spread: +486.63 pp (CLYM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
EVGN TTM Op. Margin: -858.2% CLYM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EVGN vs CLYM. Trailing 12-month operating profitability (EVGN -858.2% vs CLYM 0.0%) and valuation multiples (EVGN N/M vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EVGN (0) vs CLYM (7)
Institutional Metric EVGN CLYM Criterion Row Winner
Market Capitalization Scale $6.0M $583.9M Larger Scale CLYM
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -60.7% +0.0% Higher Growth CLYM
Operating Margin (TTM) Profitability -858.2% 0.0% Higher Margin CLYM
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -182.8% -29.3% Higher ROE CLYM
52-Week Range Position Momentum 9% ($0โ€“$1) 49% ($2โ€“$18) Stronger Trend CLYM
Beta / 30D Volatility Risk Regime 1.37ฮฒ ยท 138% Vol 1.52ฮฒ ยท 112% Vol Lower Realized Risk CLYM
Unified Institutional Score Composite Signal 44.1 / 100 (HOLD) 51.0 / 100 (HOLD) Higher Composite CLYM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EVGN vs CLYM Buy Guide
EVGN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live EVGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CLYM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLYM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EVGN nor CLYM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.